Leukemia inhibitory factor promotes tumor growth and metastasis in human osteosarcoma via activating STAT3
Bin Liu
Department of Orthopedics, Liaocheng Second People's Hospital, Linqing City, Shandong Province, China
These two authors contributed equally to this work.Search for more papers by this authorYi Lu
Department of Orthopedics, The People's Hospital of Zhangqiu City, Zhangqiu City, Shandong Province, China
These two authors contributed equally to this work.Search for more papers by this authorJinzhi Li
Department of Pathology, The People's Hospital of Zhangqiu City, Zhangqiu City, Shandong Province, China
Search for more papers by this authorYanping Liu
Department of Pediatric Gastrointestinal Surgery, The People's Hospital of Zhangqiu City, Zhangqiu City, Shandong Province, China
Search for more papers by this authorJian Liu
Department of Orthopedics, The People's Hospital of Zhangqiu City, Zhangqiu City, Shandong Province, China
Search for more papers by this authorCorresponding Author
Weiguo Wang
Department of Interventional Radiology, Affiliated Hospital of Jiangnan University and Wuxi 4th People's Hospital, Wuxi City, Jiangsu Province, China
Weiguo Wang, Huihe Road No. 200, Binhu District, Wuxi City, Jiangsu Province 214062, China. e-mail: [email protected]Search for more papers by this authorBin Liu
Department of Orthopedics, Liaocheng Second People's Hospital, Linqing City, Shandong Province, China
These two authors contributed equally to this work.Search for more papers by this authorYi Lu
Department of Orthopedics, The People's Hospital of Zhangqiu City, Zhangqiu City, Shandong Province, China
These two authors contributed equally to this work.Search for more papers by this authorJinzhi Li
Department of Pathology, The People's Hospital of Zhangqiu City, Zhangqiu City, Shandong Province, China
Search for more papers by this authorYanping Liu
Department of Pediatric Gastrointestinal Surgery, The People's Hospital of Zhangqiu City, Zhangqiu City, Shandong Province, China
Search for more papers by this authorJian Liu
Department of Orthopedics, The People's Hospital of Zhangqiu City, Zhangqiu City, Shandong Province, China
Search for more papers by this authorCorresponding Author
Weiguo Wang
Department of Interventional Radiology, Affiliated Hospital of Jiangnan University and Wuxi 4th People's Hospital, Wuxi City, Jiangsu Province, China
Weiguo Wang, Huihe Road No. 200, Binhu District, Wuxi City, Jiangsu Province 214062, China. e-mail: [email protected]Search for more papers by this authorAbstract
The leukemia inhibitory factor (LIF) has been demonstrated to be an oncogene and participated in multiple procedures during the initiation and progression of many human malignancies. However, the role of LIF in osteosarcoma is still largely unknown. Here, we performed a series of in vitro and in vivo experiments to investigate the expression and biological functions of LIF in osteosarcoma. Compared to that in the non-cancerous tissues, LIF was significantly overexpressed in a panel of 68 osteosarcoma samples (p < 0.0001). Moreover, the overexpression of LIF was significantly correlated with advanced tumor stage, larger tumor size, and shorter overall survival. In addition, knockdown of LIF notably suppressed the proliferation and invasion of osteosarcoma via blocking the STAT3 signal pathway; in contrast, treatment with the recombinant LIF protein significantly promoted the growth and invasion of osteosarcoma through enhancing the phosphorylation of STAT3, which can be partially neutralized by the STAT3 inhibitor, HO-3867. In conclusion, we demonstrated that LIF was frequently overexpressed in osteosarcoma, which could promote the growth and invasion through activating the STAT3 pathway. Our findings proposed that LIF might be a potent therapeutic target for osteosarcoma.
References
- 1Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program. Cancer 2009; 115: 1531–43.
- 2Ritter J, Bielack SS. Osteosarcoma. Ann Oncol 2010; 21(Suppl 7): vii320–5.
- 3Qureshi A, Ahmad Z, Azam M, Idrees R. Epidemiological data for common bone sarcomas. Asian Pac J Cancer Prev 2010; 11: 393–5.
- 4Bielack S, Carrle D, Casali PG, Group EGW. Osteosarcoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009; 20(Suppl 4): 137–9.
- 5Hughes DP. Strategies for the targeted delivery of therapeutics for osteosarcoma. Expert Opin Drug Deliv 2009; 6: 1311–21.
- 6PosthumaDeBoer J, Witlox MA, Kaspers GJ, van Royen BJ. Molecular alterations as target for therapy in metastatic osteosarcoma: a review of literature. Clin Exp Metastasis 2011; 28: 493–503.
- 7Turnley AM, Bartlett PF. Cytokines that signal through the leukemia inhibitory factor receptor-beta complex in the nervous system. J Neurochem 2000; 74: 889–99.
- 8Gearing DP, Gough NM, King JA, Hilton DJ, Nicola NA, Simpson RJ, et al. Molecular cloning and expression of cDNA encoding a murine myeloid leukaemia inhibitory factor (LIF). EMBO J 1987; 6: 3995–4002.
- 9Gearing DP. The leukemia inhibitory factor and its receptor. Adv Immunol 1993; 53: 31–58.
- 10Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochem J 1998; 334(Pt 2): 297–314.
- 11De Matos DG, Miller K, Scott R, Tran CA, Kagan D, Nataraja SG, et al. Leukemia inhibitory factor induces cumulus expansion in immature human and mouse oocytes and improves mouse two-cell rate and delivery rates when it is present during mouse in vitro oocyte maturation. Fertil Steril 2008; 90: 2367–75.
- 12Slaets H, Dumont D, Vanderlocht J, Noben JP, Leprince P, Robben J, et al. Leukemia inhibitory factor induces an antiapoptotic response in oligodendrocytes through Akt-phosphorylation and up-regulation of 14-3-3. Proteomics 2008; 8: 1237–47.
- 13Alexander HR, Billingsley KG, Block MI, Fraker DL. D-factor/leukaemia inhibitory factor: evidence for its role as a mediator in acute and chronic inflammatory disease. Cytokine 1994; 6: 589–96.
- 14Auernhammer CJ, Melmed S. Leukemia-inhibitory factor-neuroimmune modulator of endocrine function. Endocr Rev 2000; 21: 313–45.
- 15Kamohara H, Sakamoto K, Ishiko T, Mita S, Masuda Y, Abe T, et al. Human carcinoma cell lines produce biologically active leukemia inhibitory factor (LIF). Res Commun Mol Pathol Pharmacol 1994; 85: 131–40.
- 16Garcia-Tunon I, Ricote M, Ruiz A, Fraile B, Paniagua R, Royuela M. OSM, LIF, its receptors, and its relationship with the malignance in human breast carcinoma (in situ and in infiltrative). Cancer Invest 2008; 26: 222–9.
- 17Kuphal S, Wallner S, Bosserhoff AK. Impact of LIF (leukemia inhibitory factor) expression in malignant melanoma. Exp Mol Pathol 2013; 95: 156–65.
- 18Yu H, Yue X, Zhao Y, Li X, Wu L, Zhang C, et al. LIF negatively regulates tumour-suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers. Nat Commun 2014; 5: 5218.
- 19Arthan D, Hong SK, Park JI. Leukemia inhibitory factor can mediate Ras/Raf/MEK/ERK-induced growth inhibitory signaling in medullary thyroid cancer cells. Cancer Lett 2010; 297: 31–41.
- 20Heymann D, Godard A, Raher S, Ringeard S, Lassort D, Blanchard F, et al. Human interleukin for DA cells/leukemia inhibitory factor and oncostatin M enhance membrane expression of intercellular adhesion molecule-1 on melanoma cells but not the shedding of its soluble form. Cytokine 1995; 7: 111–7.
- 21Heymann D, Harb J, Ringeard S, Blanchard F, Lassort D, Raher S, et al. Upmodulation of alpha v beta 1 integrin expression on human tumor cells by human interleukin for DA cells/leukemia inhibitory factor and oncostatin M: correlation with increased cell adhesion on fibronectin. J Cell Biochem 1995; 58: 305–14.
- 22Humbert L, Ghozlan M, Canaff L, Tian J, Lebrun JJ. The leukemia inhibitory factor (LIF) and p21 mediate the TGFbeta tumor suppressive effects in human cutaneous melanoma. BMC Cancer 2015; 15: 200.
- 23Bay JM, Patterson BK, Teng NN. Leukemia inhibitory factor downregulates human papillomavirus-16 oncogene expression and inhibits the proliferation of cervical carcinoma cells. Infect Dis Obstet Gynecol 2011; 2011: 463081.
- 24Li J, He X, Dong R, Wang Y, Yu J, Qiu H. Frequent loss of NISCH promotes tumor proliferation and invasion in ovarian cancer via inhibiting the FAK signal pathway. Mol Cancer Ther 2015; 14: 1202–12.
- 25Suman P, Malhotra SS, Gupta SK. LIF-STAT signaling and trophoblast biology. JAKSTAT 2013; 2: e25155.
- 26Messerschmitt PJ, Garcia RM, Abdul-Karim FW, Greenfield EM, Getty PJ. Osteosarcoma. J Am Acad Orthop Surg 2009; 17: 515–27.
- 27Siclari VA, Qin L. Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res 2010; 5: 78.
- 28Liu SC, Tsang NM, Chiang WC, Chang KP, Hsueh C, Liang Y, et al. Leukemia inhibitory factor promotes nasopharyngeal carcinoma progression and radioresistance. J Clin Invest 2013; 123: 5269–83.
- 29Ye F, Hu Y, Lu W, Zhou C, Xie X. Expression of leukaemia inhibitory factor in epithelial ovarian carcinoma: correlation with clinical characteristics. Histopathology 2008; 53: 224–8.
- 30Shin JE, Park SH, Jang YK. Epigenetic up-regulation of leukemia inhibitory factor (LIF) gene during the progression to breast cancer. Mol Cells 2011; 31: 181–9.
- 31Iwamoto T, Senga T, Adachi K, Hamaguchi M. Stat3-dependent induction of interleukin-3 receptor expression in leukemia inhibitory factor-stimulated M1 mouse leukemia cells. Cytokine 2004; 25: 136–9.
- 32Quaglino A, Schere-Levy C, Romorini L, Meiss RP, Kordon EC. Mouse mammary tumors display Stat3 activation dependent on leukemia inhibitory factor signaling. Breast Cancer Res 2007; 9: R69.
- 33Schuringa JJ, van der Schaaf S, Vellenga E, Eggen BJ, Kruijer W. LIF-induced STAT3 signaling in murine versus human embryonal carcinoma (EC) cells. Exp Cell Res 2002; 274: 119–29.
